Vancomycin use is often associated with nephrotoxicity. It remains uncertain, however, to
what extent vancomycin is directly responsible, as numerous potential risk factors for acute …

Objectives: The objective of this systematic review and meta-analysis was to assess acute
kidney injury with combination therapy of vancomycin plus piperacillin-tazobactam, in …

Methods These are the consensus statements and guideline of ASHP, IDSA, the Pediatric
Infectious Diseases Society (PIDS), and SIDP. Guideline panel composition consisted of …

Purpose Although dozens of studies have associated vancomycin+ piperacillin–tazobactam
with increased acute kidney injury (AKI) risk, it is unclear whether the association represents …

Evidence suggests that maintenance of vancomycin trough concentrations at between 15
and 20 mg/liter, as currently recommended, is frequently unnecessary to achieve the daily …

Background: Recent studies have identified the combination of vancomycin with piperacillin-
tazobactam (VPT) to be associated with increased nephrotoxicity. Multiple, large cohort …

Concomitant vancomycin and piperacillin/tazobactam (PT) may be associated with
increased acute kidney injury (AKI) compared to vancomycin without PT. Medline …

Evidence supports vancomycin therapeutic-drug monitoring by area under the concentration-
time curve (AUC), but data to establish an AUC upper limit are limited and published …

Objectives The high microbiologic diversity encountered in prosthetic joint infection (PJI)
makes the choice of empirical antimicrobial therapies challenging, especially in cases of …

Purpose Standard dosing and intermittent bolus application (IB) are important risk factors for
pharmacokinetic (PK) target non-attainment during empirical treatment with β-lactams in …